Recent Updates
Recently added Catalysts
INAB Positive Sentiment

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Thursday, August 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: IN8bio, Inc. announced that CEO William Ho will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The company is focused on gamma-delta T cell-based therapies for cancer, with its lead program INB-400 in Phase 2 trials for glioblastoma (GBM). This presentation aligns with IN8bio's effort to enhance investor awareness of its ongoing clinical trials and innovative treatment approaches in the biopharmaceutical sector.
Price reaction · baseline $15.75 (2024-08-28 close) · hit after-hours · 2 other INAB headline(s) in the window, move may be shared
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • IN8bio is participating in a prominent investment conference, increasing visibility.
  • The company is advancing its innovative gamma-delta T cell therapies.
  • Lead program INB-400 is currently in a Phase 2 trial for GBM.
  • Multiple ongoing clinical trials suggest strong developmental activity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
5.4%
average across 6 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
EAGD T-cell infusion
Phase 1 · Acute Myeloid Leukemia

Full Press Release Details

NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:
H.C. Wainwright 26th Annual Global Investment Conference
Format Fireside Chat
Date/Time Monday, September 9, 2024, at 2:30 p.m. ET.
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH

Frequently Asked Questions

When will IN8bio's CEO present at the conference?

William Ho will present on September 9, 2024, at 2:30 p.m. ET.

What is IN8bio focused on developing?

IN8bio specializes in innovative gamma-delta T cell therapies for cancer.

Where can I watch the live presentation?

The presentation will be available live on IN8bio's website under 'Events and Presentations'.

What is the focus of IN8bio's lead program INB-400?

INB-400 is currently in a Phase 2 trial for glioblastoma multiforme (GBM).

What types of tumors are included in IN8bio's trials?

IN8bio's trials include solid and hematologic tumors, especially GBM.

ShareAdd on Google
Tags: INAB Viatris Investor Conferences Healthcare IN8bio gamma-delta T cell therapies cancer treatments clinical trials investment conference
Last updated: Aug 29, 2024

Biotech snapshot

Cash runway
$18M liquidity · $2M/mo burn
~11 mo
Medium dilution risk
Lead asset
EAGD T-cell infusionPhase 1
Acute Myeloid Leukemia →

Catalyst track record

+70%
best trade around INAB's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for INAB.

See every catalyst's timing & PoA →